Download PDF
Semin Liver Dis 2000; 20(4): 465-480
DOI: 10.1055/s-2000-13156
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hepatitis B and C in the Liver Transplant Recipient

Hugo R. Rosen1 , Paul Martin2
  • 1Division of Gastroenterology/Hepatology and Liver Transplantation Program, Portland Veterans Administration, and Oregon Health Sciences University, Portland, Oregon
  • 2Division of Digestive Diseases and Dumont-UCLA Transplant Program, Center for Health Sciences, University of California at Los Angeles; Los Angeles, California
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

ABSTRACT

Liver disease related to chronic viral hepatitis is the leading indication for orthotopic liver transplantation (OLT) worldwide. The evolution of our understanding of hepatitis B and C infection in the OLT recipient has been rapid in the last decade. The spontaneous risk for viral recurrence after transplantation is high but has been effectively decreased in hepatitis B infected recipients with the use of HBIG and lamivudine with dramatic improvements in patient and graft survivals. HCV recurrence as defined by histologic injury is almost universal although graft or patient outcomes for the first decade after OLT do not appear to be limited by HCV infection for most patients. However, individual patients do suffer severe graft injury and even graft loss due to recurrent HCV. With longer follow up into the second decade, the prevalence of HCV-related graft failure is likely to increase. In addition, the role of different immunosuppressive protocols on disease recurrence requires further study. Thus, although hepatitis B recurrence has been effectively contained by use of HBIG with or without lamivudine, the more intractable problem of managing recurrent HCV has as yet no obvious solutions. Optimal antiviral strategies for hepatitis C post-OLT have yet to be identified.

KEYWORD

hepatitis B - hepatitis C - viral recurrence

REFERENCES

  • 1 Todo S, Demetris A, Van Thiel D. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease.  Hepatology . 1991;  13 619
    CrossrefPubMedGoogle Scholar
  • 2 Terrault N A. Hepatitis B virus and liver transplantation.  Clini Liver Dis. 1999;  2 389-415
    PubMedGoogle Scholar
  • 3 Samuel D, Muller R, Alexander G. Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med . 1993;  329 1842-1847
    CrossrefPubMedGoogle Scholar
  • 4 Perrillo R, Rakela J, Martin P. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation.  Hepatology . 1997;  26 260A
    PubMedGoogle Scholar
  • 5 Tipples G, Ma M, Fischer K. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro.  Hepatology . 1996;  24 714
    PubMedGoogle Scholar
  • 6 Terrault N, Zhou S, McCory R W. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.  Hepatology . 1998;  28 555-559
    CrossrefPubMedGoogle Scholar
  • 7 Ghany M, Ayola B, Villamil F, Gish R. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.  Hepatology . 1998;  27 213
    CrossrefPubMedGoogle Scholar
  • 8 Chang M-H, Chen C-J, Lai M-S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.  N Engl J Med . 1997;  1855
    PubMedGoogle Scholar
  • 9 Terrault N, Pessoa M, Singleton S. Improved survival of hepatitis B patients undergoing liver transplantation: effects independent of therapeutic interventions.  Hepatology . 1997;  26 177A
    PubMedGoogle Scholar
  • 10 Davies S F, Portmann B C, O'Grady J G. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis.  Hepatology . 1991;  13 150-155
    CrossrefPubMedGoogle Scholar
  • 11 Chisari F, Klopchin K, Moriyama T. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.  Cell . 1989;  59 1145
    CrossrefPubMedGoogle Scholar
  • 12 Mason A L, Wick M, White H M. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis.  Gastroenterology . 1993;  4 1269-1270
    PubMedGoogle Scholar
  • 13 Charlton M, Seaberg E, Wiesner R. Predictors of patient and graft survival following liver transplantation for hepatitis C.  Hepatology . 1998;  28 823-830
    CrossrefPubMedGoogle Scholar
  • 14 Samuel D, Muller R, Alexander G. Liver transplantation in European patients with the hepatitis B surface antigen.  N Engl J Med . 1993;  329 1842-1847
    CrossrefPubMedGoogle Scholar
  • 15 Jurim O, Martin P, Shaked A. Liver transplantation for chronic hepatitis B in Asians.  Transplantation . 1994;  9 1393-1395
    PubMedGoogle Scholar
  • 16 Ho B M, So S K, Esquivel C O, Keeffe E B. Liver transplantation in Asian patients with chronic hepatitis B.  Hepatology . 1997;  1 223-225
    PubMedGoogle Scholar
  • 17 So S K, Esquivel C O, Imperial J C. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?.  J Gastroenterol Hepatol . 1999;  28(Suppl) S48-S53
    PubMedGoogle Scholar
  • 18 Crippin J, Foster B, Carlen S. Retransplantation for hepatitis B - A multicenter experience.  Transplantaton . 1994;  6 823-826
    PubMedGoogle Scholar
  • 19 Ishitani M, McGory R, Dickson R. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft.  Transplantation . 1997;  3 410-414
    PubMedGoogle Scholar
  • 20 Roche B, Samuel D, Feray C. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience.  Liver Transpl Surg . 1999;  3 166-174
    PubMedGoogle Scholar
  • 21 Omata M, Ehata T, Yokosuka O. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis.  N Engl J Med . 1991;  324 1699
    PubMedGoogle Scholar
  • 22 Belle S, Beringer K, Detre K. Long-term outcome of liver transplant recipients in the US.  Clinical Transplants . 1995;  19-31
    PubMedGoogle Scholar
  • 23 Naumann U, Protzer-Knolle U, Berg T. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis.  Hepatology . 1997;  2 478-484
    PubMedGoogle Scholar
  • 24 Ottobrelli A, Marzano A, Smedile A. Patterns of hepatitis delta virus reinfection and disease in liver transplantation.  Gastroenterology . 1991;  101 1649-1654
    PubMedGoogle Scholar
  • 25 Huang E J, Wright T L, Lake J R, Combs C, Ferrell L D. Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation.  Hepatology . 1996;  3 396-404
    PubMedGoogle Scholar
  • 26 Pessoa M, Kim E, Martin P. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin in reducing the incidence of acute rejection post transplantation.  Gastroenterology . 1998;  114 A1322
    PubMedGoogle Scholar
  • 27 Samuel D, Zignego A, Reynes M. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.  Hepatology . 1995;  21 333
    CrossrefPubMedGoogle Scholar
  • 28 Smedile A, Casey J L, Cote P J, Durazzo M, Lavezzo B, Purcell R H, Rizzetto M, Gerin J L. Hepatitis D Viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope.  Hepatology . 1998;  6 1723-1729
    PubMedGoogle Scholar
  • 29 Alberti A, Pontisso P, Chemello L. The interaction between hepatitis B and hepatitis C virus in acute and chronic liver disease.  J Hepatology . 1995;  2(Suppl) 38-41
    PubMedGoogle Scholar
  • 30 Feray C, Gigou M, Samuel D. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation.  Ann Intern Med . 1998;  10 810-816
    PubMedGoogle Scholar
  • 31 Dickson R C, Everhart J E, Lake J R. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen.  Gastroenterology . 1997;  5 1668-1674
    PubMedGoogle Scholar
  • 32 Uemoto S, Sugiyama K, Marusawa H. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants.  Transplantation . 1998;  4 494-499
    PubMedGoogle Scholar
  • 33 Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando M E, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.  N Engl J Med . 1999;  341 22-26
    CrossrefPubMedGoogle Scholar
  • 34 Dodson S F, Issa S, Araya V. Infectivity of hepatic allografts with antibodies to hepatitis B virus.  Transplantation . 1997;  11 1582-1584
    PubMedGoogle Scholar
  • 35 Crespo J, Fabrega E, Casafont F. Severe clinical course of de novo hepatitis B infection after liver transplantation.  Liver Transpl Surg . 1999;  3 175-183
    PubMedGoogle Scholar
  • 36 Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med . 1996;  11 693-699
    PubMedGoogle Scholar
  • 37 Wong P Y, McPeake J R, Portmann B. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma.  Am J Gastroenterol . 1995;  1 29-34
    PubMedGoogle Scholar
  • 38 Mazzaferro V, Regalia E, Montalto F. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence.  Liver . 1996;  2 117-122
    PubMedGoogle Scholar
  • 39 Berenguer M, Wright T L. Antiviral therapy before and after liver transplantation. In: Sorrell M, Maddrey WC, eds. Liver Transplantation (3rd ed); (in press)
    Google Scholar
  • 40 Terrault N A, Combs H C, Ferrel L. Interferon alpha for recurrent hepatitis B infection after liver transplantation.  Liver Transpl Surg . 1996;  2 132-138
    PubMedGoogle Scholar
  • 41 Bain V G, Kneteman N M, Ma M M. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation.  Transplantation . 1996;  62 1456-1462
    PubMedGoogle Scholar
  • 42 Perrillo R, Rakela J, Dienstaag J. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.  Hepatology . 1999;  29 1581-1586
    PubMedGoogle Scholar
  • 43 Fontana R J, Keeffe E B, Han S. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients.  Hepatology . 1999;  30 301A
    PubMedGoogle Scholar
  • 44 Mutimer D, Pillay D, Shields P. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient.  Gut . 2000;  46 107-113
    CrossrefPubMedGoogle Scholar
  • 45 Villeneuve J P, Condreay L D, Willems B. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.  Hepatology . 2000;  31 207-210
    CrossrefPubMedGoogle Scholar
  • 46 Markowitz J S, Martin P, Conrad A J. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.  Hepatology . 1998;  28 585-589
    CrossrefPubMedGoogle Scholar
  • 47 Yao F Y, Osorio R W, Roberts J P. Intramuscular hepatitis B immune globulin continued with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.  Liver Transpl Surg . 1999;  5 491-496
    CrossrefPubMedGoogle Scholar
  • 48 Sanchez-Fueyo A, Rimola A, Grande L. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.  Hepatology . 2000;  31 496-501
    CrossrefPubMedGoogle Scholar
  • 49 Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections.  Gastroenterology . 2000;  118 S83-S103
    CrossrefPubMedGoogle Scholar
  • 50 Alter M J. The epidemiology of acute and chronic hepatitis C.  Clin Liver Dis . 1997;  1 559-568
    PubMedGoogle Scholar
  • 51 Gane E. Hepatitis C virus infection following liver transplantation.  Viral Hepat Rev . 1998;  4 97-125
    PubMedGoogle Scholar
  • 52 Rosen H R, Gretch D R. Hepatitis C virus: molecular aspects and implications for future therapy.  Molecular Medicine Today . 1999;  5 393-399
    CrossrefPubMedGoogle Scholar
  • 53 Koziel M J, Dudley D, Afdhal N. Hepatitis C virus-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV.  J Virol . 1993;  67 7522-7532
    PubMedGoogle Scholar
  • 54 Ferrari C, Valli A, Galati L. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections.  Hepatology . 1994;  9 286-295
    PubMedGoogle Scholar
  • 55 Tong M J, El-Farra N A, Reikes A R. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med . 1995;  332 1463-1466
    CrossrefPubMedGoogle Scholar
  • 56 Missale G, Bertoni R, Lamonaca V. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.  J Clin Invest . 1996;  98 706-714
    PubMedGoogle Scholar
  • 57 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
    CrossrefPubMedGoogle Scholar
  • 58 Fattovich G, Giustina G, Degos F. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients.  Gastroenterology . 1997;  112 463-472
    CrossrefPubMedGoogle Scholar
  • 59 Gane E J, Naoumov N V, Qian K-P. A longitudinal analysis of hepatitis C virus replication following liver transplantation.  Gastroenterology . 1996;  110 167-177
    CrossrefPubMedGoogle Scholar
  • 60 Fukumoto T, Berg T, Ku Y. Viral Dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.  Hepatology . 1996;  24 1351-1354
    PubMedGoogle Scholar
  • 61 Boker K, Dalley G, Bahr M. Long-term outcome of hepatitis C virus infection after liver transplantation.  Hepatology . 1997;  25 203-210
    PubMedGoogle Scholar
  • 62 Rosen H R, O'Reilly P M, Shackleton C R. Graft loss following liver transplantation in patients with chronic hepatitis C.  Transplantation . 1996;  62 1773-1776
    CrossrefPubMedGoogle Scholar
  • 63 Gane E J, Portmann B C, Naoumouv N V. Long-term outcome of hepatitis C infection after liver transplantation.  N Eng J Med . 1996;  334 821-827
    PubMedGoogle Scholar
  • 64 Rosen H R, Gretch D R, Oehlke M. Timing and severity of hepatitis C recurrence following liver transplantation as predictors of longterm allograft injury.  Transplantation . 1998;  65 1178-1182
    PubMedGoogle Scholar
  • 65 Prieto M, Berenguer M, Rayon J M. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.  Hepatology . 1999;  29 250-256
    CrossrefPubMedGoogle Scholar
  • 66 Dickson R C, Caldwell S H, Ishitani M B, Lau J YN, Driscoll C J, Stevenson W C. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation.  Transplantation . 1996;  61 701-705
    PubMedGoogle Scholar
  • 67 Schluger L K, Sheiner P A, Thung S N. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.  Hepatology . 1996;  23 971-976
    PubMedGoogle Scholar
  • 68 Chazouilleres O, Kim M, Combs C. Quantitation of hepatitis C virus RNA in liver transplant recipients.  Gastroenterology . 1994;  106 994-999
    PubMedGoogle Scholar
  • 69 Gretch D R, Bacchi C E, Corey L, delaRosa C, Lesniewski R R, Kowdley K, Gown A, Frank I, Perkins J D, Carithers R L. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features.  Hepatology . 1995;  22 1-9
    CrossrefPubMedGoogle Scholar
  • 70 Feray C, Gigou M, Samuel D. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation.  Gastroenterology . 1995;  108 1088-1096
    PubMedGoogle Scholar
  • 71 Vargas H E, Laskus T, Wang L F. The influence of hepatitis C virus genotype on the outcome of liver transplantation.  Liver Transpl Surg . 1997;  4 22-27
    PubMedGoogle Scholar
  • 72 Zhou S, Terrault N A, Ferrell L, Hahn J A, Lau J YN, Simmonds P. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia.  J Hepatology . 1996;  24 1041-1046
    PubMedGoogle Scholar
  • 73 Shuhart M C, Bronner M P, Gretch D R. Histological and clinical outcome after liver transplantation for hepatitis C.  Hepatology . 1997;  26 1646-1652
    PubMedGoogle Scholar
  • 74 Gonzalez-Peralta R, Lau J YN. Do viral genotypes and HLA matching influence the outcome of recurrent hepatitis C virus infection after liver transplantation?.  Liver Transpl Surg . 1998;  4 104-108
    CrossrefPubMedGoogle Scholar
  • 75 Berenguer M, Prieto M, Cordoba J. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.  J Hepatol . 1998;  28 756-763
    CrossrefPubMedGoogle Scholar
  • 76 Gretch D R, Polyak S J, Wilson J J. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients.  J Virology . 1996;  70 7622-7631
    PubMedGoogle Scholar
  • 77 Sullivan D G, Wilson J J, Carithers R L, Perkins J D, Gretch D R. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns.  J Virology . 1998;  72 10036-10043
    PubMedGoogle Scholar
  • 78 Ghobrial R M, Colquhoun S, Rosen H R. Tacrolimus versus cyclosporine immunosuppression in liver transplantation for hepatitis C.  Hepatology . 1998;  28 261A[abstract]
    PubMedGoogle Scholar
  • 79 Zervos X A, Weppler D, Fragulidis G P. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation.  Transplantation . 1998;  65 1044-1046
    CrossrefPubMedGoogle Scholar
  • 80 Wiesner R H, and the United States FK506 Study Group. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation.  Transplantation . 1998;  66 493-499
    CrossrefPubMedGoogle Scholar
  • 81 Martin P, Goldstein R M, Goss J. A prospective controlled trial of tacrolimus vs. cyclosporine in orthotopic liver transplant recipients with hepatitis C virus: lack of effect on recurrent hepatitis.  Hepatology . 1998;  28 313A
    PubMedGoogle Scholar
  • 82 Rosen H R, Martin P. Liver Transplantation. In: Schiff ER, Maddrey WC, Sorrell MF, eds. Schiff's Disorders of Liver Disease, 8th ed Philadelphia: Lippincott-Raven 1999: 1589-1615
    Google Scholar
  • 83 Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of NIDDK Liver Transplantation Database.  Liver Transpl Surg . 1999;  5 S107-S114
    CrossrefPubMedGoogle Scholar
  • 84 Sheiner P A, Schwartz M E, Mor E. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.  Hepatology . 1995;  21 30-34
    CrossrefPubMedGoogle Scholar
  • 85 Rosen H R, Shackleton C R, Farmer D A. Use of OKT3 (monoclonal antibody) associated with early and severe hepatitis C recurrence following liver transplantation.  Am J Gastroenterol . 1997;  92 1453-1456
    PubMedGoogle Scholar
  • 86 Rosen H R, Martin P. OKT3 and hepatitis C: Defining the risks.  Transplantation . 1997;  63 171-172
    PubMedGoogle Scholar
  • 87 Rosen H R, Chou S, Gretch D R. Cytomegalovirus viremia: risk factor for allograft cirrhosis following liver transplantation for hepatitis C.  Transplantation . 1997;  64 721-726
    PubMedGoogle Scholar
  • 88 Charlton M, Seaberg E C, Wiesner R H. Increased mortality following CMV infection in patients transplanted for HCV: results of the NIDDK liver transplantation database.  Hepatology . 1998;  4 345A
    PubMedGoogle Scholar
  • 89 Rosen H R, Hinrichs D J, Gretch D R. Association of Multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation.  Gastroenterology. 1999;  117 926-932 1012-1014
    PubMedGoogle Scholar
  • 90 Asanza C, Garcia-Monzon C, Clemente G. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation.  Hepatology . 1997;  26 755-763
    CrossrefPubMedGoogle Scholar
  • 91 Gane E. The role of TNF-alpha in HCV recurrence following liver transplantation.  (in press).
    PubMedGoogle Scholar
  • 92 Rosen H R, Lentz J J, Rose S L. Donor polymorphism of tumor necrosis factor gene associated with variable severity of hepatitis C recurrence following liver transplantation.  Transplantation . 1999;  68 1898-1902
    PubMedGoogle Scholar
  • 93 Singh N, Gayowski T, Wagener M M, Marino I R. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis.  Transplantation . 1996;  61 402-406
    PubMedGoogle Scholar
  • 94 Negro F, Gijostra E, Rubbia-Brandt L. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.  J Med Virol . 1998;  56 224-229
    CrossrefPubMedGoogle Scholar
  • 95 Crespo J, Carte B, Lozano J L. Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia.  Am J Gastro . 1997;  9 1458-1462
    PubMedGoogle Scholar
  • 96 Rosen H R, Gretch D R, Kaufman E, Quan S. The humoral immune response to hepatitis C following liver transplantation: assessment of a new immunoblot assay.  Am J Gastro (in press).
    PubMedGoogle Scholar
  • 97 Ishitani M, McGory R, Dickson R. Late hepatic artery thrombosis: a potential complication of viral hepatitis.  Hepatology . 1996;  24 293A
    PubMedGoogle Scholar
  • 98 Altraif I H, Abdulla A S, al Sebayel I M. Hepatitis C associated glomerulonephritis.  Am J Nephrol . 1995;  15 407-410
    PubMedGoogle Scholar
  • 99 Johnson L B, Edwards E, Rustgi V K, Plotkin J S, Kuo P C. Impact of donor hepatitis C infection on recipient outcome following liver transplantation in the hepatitis C positive recipient: an analysis of the UNOS data.  Hepatology . 1998;  28 388A
    PubMedGoogle Scholar
  • 100 Vargas H E, Laskus T, Wang L-F. Outcome of liver transplantation in hepatitis C virus-infected grafts.  Gastroenterology . 1999;  117 149-155
    CrossrefPubMedGoogle Scholar
  • 101 Rosen H R, Martin P. Hepatitis C infection in patients undergoing liver retransplantation.  Transplantation . 1998;  66 1612-1616
    CrossrefPubMedGoogle Scholar
  • 102 Casavilla F A, Lee R, Lim J, Kramer D. Outcome of liver retransplantation for recurrent hepatitis C infection.  Hepatology . 1995;  22 153A
    PubMedGoogle Scholar
  • 103 Feray C, Habsanne A, Samuel D. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus.  J Hepatology . 1995;  22 135A
    PubMedGoogle Scholar
  • 104 Carithers R L. Recurrent hepatitis C after liver transplantation.  Liver Transpl Surg . 1997;  3 S16-S19
    PubMedGoogle Scholar
  • 104b Rosen H R. Retransplantation for hepatitis C: implications of different policies.  Liver Transpl . 2000;  6 41S-46S
    CrossrefPubMedGoogle Scholar
  • 105 Berenguer M, Wright T L. Treatment strategies for recurrent hepatitis C after liver transplantation.  Clin Liver Dis . 1998;  3 883-899
    PubMedGoogle Scholar
  • 106 Lavezzo B, Rizzetto M. Treatment of recurrent hepatitis C virus infection after liver transplantation.  J Hepatol . 1999;  31(Suppl) 222-226
    CrossrefPubMedGoogle Scholar
  • 107 Wright T L, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, Wilber J, Sheridan P, Urdea M. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.  Hepatology . 1994;  20 773-779
    PubMedGoogle Scholar
  • 108 Feray C, Samuel D, Gigou M. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection.  Hepatology . 1995;  22 1084-1089
    CrossrefPubMedGoogle Scholar
  • 109 Gane E J, Lo S K, Riordan S M. A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation.  Hepatology . 1998;  27 1403-1407
    CrossrefPubMedGoogle Scholar
  • 110 Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients.  N Engl J Med . 1994;  330 1160-1161
    CrossrefPubMedGoogle Scholar
  • 111 Cattral M S, Hemming A W, Wanless I R. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.  Transplantation . 1999;  67 1277-1280
    PubMedGoogle Scholar
  • 112 Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.  Hepatology . 1997;  26 500-504
    CrossrefPubMedGoogle Scholar
  • 113 Lavezzo B, Leone N, Smedile A. Combination therapy of interferon alpha 2-b and ribavirin for recurrent hepatitis C after liver transplantation.  J Hepatol . 1999;  30(Suppl 1) 67
    PubMedGoogle Scholar
  • 114 Gopal D, Rabkin J M, Berk B. Treatment of progressive HCV recurrence following liver transplatation with combination interferon and ribavirin therapy.  (in press).
    PubMedGoogle Scholar
  • 115 Sheiner P, Boros O, Klion F M. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.  Hepatology . 1998;  28 831-838
    CrossrefPubMedGoogle Scholar
  • 116 Reddy K R, Weppler D, Zervos X A. Recurrent HCV infection following OLTX.  Hepatology . 1996;  24(Suppl) 295A
    PubMedGoogle Scholar
  • 117 Singh N, Gayowski T, Wannstedt C. Interferon-a for prophylaxis of recurrent hepatitis C in liver transplant recipients.  Transplantation . 1998;  65 82-86
    CrossrefPubMedGoogle Scholar
  • 118 Mazzaferro V, Regalia E, Pulvirenti A. Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination.  Transplant Proc . 1997;  29 519-521
    CrossrefPubMedGoogle Scholar
  • 119 Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues.  J Viral Hepat . 2000;  7 87-92
    CrossrefPubMedGoogle Scholar
  • 120 Feray C, Caccamo L, Alexander G J. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.  Gastroenterology . 1999;  117 619-625
    PubMedGoogle Scholar
  • 121 Gayowski T, Singh N, Keyes L. Late-onset renal failure after liver transplantation: role of posttransplant alcohol use.  Transplantation . 2000;  69 383-388
    PubMedGoogle Scholar
  • 122 Paterson D L, Gayowski T, Wannstedt C F. Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis.  Clin Transpl . 2000;  14 48-54
    PubMedGoogle Scholar
      >